Seroquel (Quetiapine Fumarate, immediate release, IR) and Seroquel XR (extended release formulation)

• The two products are atypical, anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder.
• Seroquel XR is also approved in some markets for major depressive disorder and generalized anxiety disorder.

 

The acquisition completed in June 2018. Acquired assets including:

• Marketing authorizations, regulatory information, certain patents, relevant business materials and data, manufacturing know-how and sales networks, etc. in the 51 countries and regions
• Exclusive, permanent, free and sub-licensable trademark licensing, along with other licensing rights
• Luye Pharma will be the future production base for the global supply of Seroquel and Seroquel XR

 

Strategy behind the Acquisition

• Building a product portfolio with a global competitive edge in central nervous system therapeutic area
• Enhancing the synergy across international markets
• Enhancing brand equity